XASXNXS
Market cap19mUSD
Jan 08, Last price
0.11AUD
1D
-8.70%
1Q
-46.15%
IPO
-93.73%
Name
Next Science Ltd
Chart & Performance
P/E
—
P/S
0.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.49%
Rev. gr., 5y
42.81%
Revenues
22m
+31.27%
Net income
-25m
L+33.98%
CFO
-23m
L+33.40%
Earnings
Feb 28, 2025
Profile
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 22,179 31.27% | 16,896 41.73% | ||||||
Cost of revenue | 38,206 | 28,615 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (16,027) | (11,719) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 4 | |||||||
Tax Rate | ||||||||
NOPAT | (16,027) | (11,719) | ||||||
Net income | (24,513) 33.98% | (18,296) 46.88% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 20,381 | 14,762 | ||||||
BB yield | -25.61% | -10.24% | ||||||
| Debt | ||||||||
Debt current | 195 | 380 | ||||||
Long-term debt | 1,649 | 2,381 | ||||||
Deferred revenue | 550 | 1,216 | ||||||
Other long-term liabilities | 6 | 45 | ||||||
Net debt | (7,432) | (4,776) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (22,687) | (17,007) | ||||||
CAPEX | (433) | (686) | ||||||
Cash from investing activities | (1,298) | (686) | ||||||
Cash from financing activities | 20,108 | 14,782 | ||||||
FCF | (14,901) | (12,174) | ||||||
| Balance | ||||||||
Cash | 9,277 | 7,537 | ||||||
Long term investments | ||||||||
Excess cash | 8,168 | 6,692 | ||||||
Stockholders' equity | 12,821 | 11,849 | ||||||
Invested Capital | 6,171 | 7,760 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 234,095 | 210,468 | ||||||
Price | 0.34 -50.36% | 0.69 -44.98% | ||||||
Market cap | 79,592 -44.79% | 144,171 -41.18% | ||||||
EV | 72,160 | 139,394 | ||||||
EBITDA | (16,027) | (10,425) | ||||||
EV/EBITDA | ||||||||
Interest | 736 | 41 | ||||||
Interest/NOPBT | ||||||||